When and where do synucleinopathies begin?

Neurology

Volumn 75, Issue 6, 2010, Pages 488-489

  Mahowald, Mark W ^a   Cramer Bornemann, Michel A ^a   Schenck, Carlos H ^b  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BISOPROLOL; GROWTH FACTOR; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SYNUCLEIN; TRICYCLIC ANTIDEPRESSANT AGENT;

AUTONOMIC NERVOUS SYSTEM; BRAIN DEPTH STIMULATION; BRAIN STEM; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DREAM; EARLY DIAGNOSIS; EDITORIAL; ELECTROENCEPHALOGRAM; FOLLOW UP; HUMAN; MUSCLE ATONIA; PARASOMNIA; PARKINSON DISEASE; POLYSOMNOGRAPHY; PREMOTOR CORTEX; PRIORITY JOURNAL; PURE AUTONOMIC FAILURE; QUANTITATIVE ANALYSIS; REM SLEEP WITHOUT ATONIA; SEX DIFFERENCE; SHY DRAGER SYNDROME; SLEEP DISORDER; SUBSTANTIA NIGRA; SYNUCLEINOPATHY; AGE; ANIMAL; BIOSYNTHESIS; DIFFERENTIAL DIAGNOSIS; LEWY BODY; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOLOGY; PHYSIOLOGY; REM SLEEP BEHAVIOR DISORDER; SEXUAL DEVELOPMENT;

AGE FACTORS; ANIMALS; DIAGNOSIS, DIFFERENTIAL; HUMANS; LEWY BODIES; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; REM SLEEP BEHAVIOR DISORDER; SEX CHARACTERISTICS; SYNUCLEINS;

EID: 77955470657     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181ec804a     Document Type: Editorial

References (12)

1. BenabidAL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 2009;8: 67-81.
2. Fitzpatrick KM, Raschke J, Emborg ME. Cell-based therapies for Parkinson's disease: past, present, and future. Antioxidants Redox Signaling 2009;11:2189-2208.
3. Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010;75:494-499.
4. Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009;72:1296-1300.
5. Mahowald MW. Does "idiopathic" REM sleep behavior disorder exist? Sleep 2006;29:874-875.
6. Iranzo A, Santamaria J, Tolosa E. The clinical and pathophysiological relevance of REM sleep behavior disorder in neurodegenerative diseases. Sleep Med Rev 2009;13:385-401.
7. Marras C, Lang A. Changing concepts in Parkinson's disease. Neurology 2008;70:1996-2003.
8. Orimo S, Uchihara T, Nakamura A, et al. Axonal a-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 2008;131:642-650.
9. Gaig C, Tolosa E. When does Parkinson's disease begin? Mov Disord 2009;24:S656-S664.
10. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006;59:591-596.
11. Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 2009;8:1158-1171.
12. Ravina B, Tanner C, DiEuliis D, et al. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord 2009;24:2081-2090.